Focus on biosimilar etanercept – bioequivalence and interchangeability
Fabrizio Cantini,1 Maurizio Benucci2 1Department of Rheumatology, Hospital of Prato, Prato, Italy; 2Rheumatology Unit, Hospital S. Giovanni di Dio, Florence, Italy Background: The recent approval of reference etanercept (re-ETN) biosimilars SB4, GP2015, and HD203 produced relevant changes in the man...
Guardado en:
Autores principales: | Cantini F, Benucci M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c540f359f2044d96b0363c07a318a60c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli D, et al.
Publicado: (2016) -
Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey
por: Isabelle Arnet, et al.
Publicado: (2021) -
Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
por: Abdalla A, et al.
Publicado: (2017) -
Biosimilars: presumption of guilt
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011) -
Electronic Document Interchange in the Contractual Relationship
por: Shastitko A.Ye., et al.
Publicado: (2018)